Tarlatamab

Tarlatamab (タルラタマブ)

一行要約

DLL3×CD3 half-life extended BiTE (bispecific T-cell engager)。DeLLphi-304 phase III (Mountzios et al. NEnglJMed 2025) が既治療 ES-SCLC 509 例で化学療法 (topotecan / lurbinectedin / amrubicin) に対し OS superiority を実証し (13.6 vs 8.3 mo; HR 0.60; P < 0.001)、SCLC 2L で OS benefit を phase III で証明した初の薬剤 となった。さらに DeLLphi-303 (Paulson et al. LancetOncol 2025) が 1L maintenance (tarlatamab + PD-L1 inhibitor) で mOS 25.3 mo を報告し、1L 展開の道筋を開いた。DLL3 は neuroendocrine tumor の 80-90% に高発現し正常組織ではほぼ検出されないため therapeutic window が極めて広い。Step-up dosing (1 mg → 10 mg) で CRS を grade 3+ 約3% に管理。Rova-T (DLL3-targeted-therapy の ADC approach) の失敗教訓を踏まえ、internalization 不要の BiTE platform が DLL3 標的治療の break-through modality として確立された。

メンバー比較表

薬剤	種別	製品名	構造	標的	主要試験	承認状況	備考
Tarlatamab	BiTE (T cell engager)	Imdelltra	DLL3×CD3ε bispecific + anti-albumin HLE domain	DLL3 (tumor) + CD3ε (T cell)	DeLLphi-300/301/303/304/305	FDA 承認 2024 (SCLC 2L+)、regular approval 予定	Step-up dosing、q2w
Rovalpituzumab tesirine (Rova-T)	ADC	—	DLL3 mAb + PBD dimer payload	DLL3	TRINITY / TAHOE / MERU	開発中止	PBD 毒性 + DLL3 internalization 不足
DLL3 CAR-T	CAR-T	—	DLL3 scFv-CAR construct	DLL3	前臨床 / Phase I	前臨床	Solid tumor barriers

主要エビデンス

DeLLphi-304 (Phase III — 2L SCLC OS superiority)

• Mountzios et al. NEnglJMed 2025: ES-SCLC platinum-based chemo 後進行 509 名を tarlatamab 10 mg q2w vs investigator’s choice chemotherapy (topotecan / lurbinectedin / amrubicin) に 2:1 randomize。OS (primary endpoint) : 13.6 vs 8.3 mo (HR 0.60; 95% CI 0.47-0.77; P < 0.001)。PFS: 4.6 vs 2.1 mo (HR 0.44; 95% CI 0.35-0.55)。ORR: 51% vs 20%。mDOR: 9.7 vs 5.6 mo。CRS: grade 1-2 約51%、grade 3+ 約3% (step-up dosing + dexamethasone premedication で管理)。ICANS: grade 1-2 約5%、grade 3+ < 1%。SCLC 2L で phase III OS superiority を実証した初の agent → FDA regular approval への conversion 予定

DeLLphi-301 (Phase II — accelerated approval 根拠)

• ES-SCLC ≥2L 188 例に tarlatamab 10 mg vs 100 mg q2w。10 mg: ORR 40% (CR 5%)、mDOR 9.7 mo、mPFS 4.9 mo、mOS 14.3 mo。100 mg: ORR 32%。Low dose が efficacy / safety balance で preferred。CRS: 10 mg 群 grade 1-2 51%、grade 3+ 1%。Prior IO treatment (約90% の患者が 1L IO+chemo 既投与) でも ORR 38% → IO 後の BiTE 活性 confirm → 2024 年 5 月 FDA accelerated approval
• Durability: Responses are durable (mDOR 9.7 mo) で、一部の患者は 12 mo 以上 ongoing response → chronic disease management の可能性

DeLLphi-303 (Phase Ib — 1L maintenance)

• Paulson et al. LancetOncol 2025: ES-SCLC 1L chemo-IO (IMpower133 / CASPIAN type) 後の maintenance 88 例で tarlatamab + PD-L1 inhibitor (atezolizumab or durvalumab) を評価。mOS 25.3 mo (95% CI 20.3–NE)。12 mo OS rate 約72%。Safety manageable: CRS grade 3+ 約2%、新規 safety signal なし
• Historical comparison: 1L IO+chemo の historical mOS 12-13 mo に対し、mOS 25.3 mo は nearly double。DeLLphi-305 (phase III) confirmation 待ちだが、remarkable signal
• IMforte との positioning: Paz-Ares et al. Lancet 2025 の lurbinectedin + atezolizumab maintenance (mOS 13.2 mo from maintenance) と直接比較は困難だが、DeLLphi-303 の mOS 25.3 mo は numerically superior → head-to-head comparison が将来的に必要

DeLLphi-300 (Phase I — dose/schedule 確立)

• First-in-human dose escalation / expansion。Tarlatamab 0.003-100 mg の dose range を探索。PK: half-life extended (anti-albumin domain) により q2w 投与が可能。ORR 23.4% (dose escalation 全体) → 10 mg q2w が RP2D。Step-up dosing (C1D1 1 mg → C1D15 10 mg) で CRS peak を C1D1 に限局 (low dose priming effect)

DeLLphi-305 (Phase III — 1L concurrent/maintenance、ongoing)

• 1L platinum/etoposide + IO + tarlatamab (concurrent → maintenance) vs standard 1L (platinum/etoposide + IO) の phase III。Primary endpoint OS。SCLC の 1L treatment paradigm 変革を目指す。DeLLphi-303 の signal (mOS 25.3 mo) が confirmation されれば、SCLC 全 line で tarlatamab が backbone 化

Rova-T との比較と ADC 失敗の教訓

• Rova-T ADC paradigm: Saunders et al. SciTranslMed 2015 が DLL3 を target として同定し Rova-T concept を確立。TRINITY phase II: ORR 12.4%、mOS 5.6 mo (Morgensztern et al. ClinCancerRes 2019)。TAHOE / MERU phase III: いずれも futility → 開発中止
• ADC 失敗の 3 要因: (1) PBD payload の long half-life → off-target systemic toxicity、(2) DLL3 の Golgi 優位局在 → cell surface trafficking 不足 → ADC の receptor-mediated endocytosis に不利、(3) DLL3 surface density が ADC に必要な threshold 未達
• BiTE の advantage: Internalization 不要 (surface DLL3 に engage するだけで T cell activation) → DLL3 の低 surface density でも機能。Off-the-shelf IV 投与、dose titration 容易 (CRS を step-up で制御)

Preclinical foundation

• Giffin et al. ClinCancerRes 2021: AMG 757 (tarlatamab) の前臨床データ。SCLC cell line / CDX model で potent T cell redirected killing。DLL3 low-expressing cell でも activity confirm → clinical dose selection の基盤

メカニズム

BiTE Platform と半減期延長

Tarlatamab は half-life extended bispecific T-cell engager (HLE-BiTE) で、以下の 3 ドメインからなる:

1. DLL3-binding arm: Single-chain variable fragment (scFv) が DLL3 extracellular domain に結合
2. CD3ε-binding arm: scFv が T cell surface の CD3ε に結合
3. Anti-albumin domain (HLE) : 血中 albumin に結合し半減期を 約3-5 日に延長 → q2w 投与 を実現。初代 BiTE (blinatumomab) は continuous IV infusion (28 days) が必要だったが、HLE technology で ambulatory dosing が可能に

T cell Redirected Killing のステップ

1. DLL3 arm engagement: Tarlatamab が腫瘍細胞表面の DLL3 に結合。DLL3 は Golgi 局在が主体だが、cell surface にも一定量 traffic する。BiTE は internalization 不要 → 低レベル surface expression でも engagement 可能 (ADC との決定的差異)
2. CD3ε arm engagement: 同一 tarlatamab 分子の CD3 arm が近傍 T cell の TCR-CD3 complex に結合
3. Immunological synapse 形成: Tumor cell-T cell の近接化 → non-classical immunological synapse の形成
4. Polyclonal T cell activation: TCR の MHC/peptide recognition non-依存的 に T cell が活性化 → granzyme B / perforin の exocytosis → 標的細胞の apoptosis。MHC-I downregulation した SCLC (IO 耐性の一因) にも有効
5. Serial killing: 1 T cell が sequential に複数の tumor cell を killing (BiTE の catalytic nature)
6. Bystander cytokine effect: Activated T cell が IFN-γ / TNF-α を放出 → 近傍 DLL3-negative cell にも間接的殺傷 → intra-tumoral DLL3 heterogeneity を部分的に克服

DLL3 Biology (Cross-reference: DLL3、DLL3-targeted-therapy)

• SCLC の 80-90% で DLL3 陽性 (IHC ≥1%)。正常成人組織ではほぼ発現なし (脳下垂体に微弱のみ) → tumor-restricted target
• ASCL1-DLL3 transcriptional axis: Borromeo et al. CellRep 2016 が ASCL1 による DLL3 直接転写駆動を実証。SCLC-A subtype (約70%) で最高発現
• Notch cis-inhibition: DLL3 は trans-activation 能を欠き、同一細胞内で Notch mature form の surface trafficking を阻害 (cis-inhibition) → Notch off → NE program 維持
• MYC-driven subtype evolution: Ireland et al. CancerCell 2020 — MYC-driven ASCL1→NEUROD1→YAP1 transition に伴い DLL3 発現が低下 → acquired resistance の分子基盤

CRS (Cytokine Release Syndrome) の機序と管理

CRS は BiTE class の on-target / off-tumor effect で、T cell activation に伴う IL-6 / IL-1β / IFN-γ / TNF-α の急激な全身放出:

Step-up dosing protocol (DeLLphi-304) :

• Cycle 1 Day 1: 1 mg (low dose priming) → T cell が low-level activation → cytokine release peak を C1D1 に限局
• Cycle 1 Day 15: 10 mg (full dose) → Primed T cell は 2nd exposure で cytokine release が attenuated
• Cycle 2 以降: 10 mg q2w
• 入院モニタリング: C1D1-D2 および C1D15-D16 推奨
• Premedication: Dexamethasone (C1D1 / C1D15 前日〜当日)

Grade	症状	DeLLphi-304 頻度	管理
Grade 1	発熱のみ	約30%	解熱薬 + 経過観察
Grade 2	低血圧 (輸液で改善) / 低酸素	約18%	輸液 + tocilizumab 検討
Grade 3+	昇圧薬必要 / 人工呼吸	約3%	Tocilizumab + dexamethasone + ICU

ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome)

• Tarlatamab では grade 1-2 headache / confusion が 約5%、grade 3+ は < 1%
• Mechanism: BBB の cytokine-mediated permeability 亢進 → CNS endothelial activation → cerebral edema
• 管理: Neurological assessment routine 実施、grade 2+ で dexamethasone + dose hold

耐性メカニズム

• DLL3 downregulation / loss: MYC-driven NE→non-NE transition (Ireland et al. CancerCell 2020) に伴う DLL3 転写消失が主要 acquired resistance pathway
• T cell exhaustion: Chronic BiTE exposure → PD-1 / TIM-3 / LAG-3 upregulation on redirected T cells → effector function 低下。IO combination (DeLLphi-303 / 305) が exhaustion rescue strategy
• MHC-I independent 殺傷だが TME immunosuppression は bypass できない: Treg / MDSC / IDO1 による TME suppression は T cell redirected killing 自体を阻害する
• DLL3 IHC と response: DeLLphi-301 subgroup 解析で DLL3-high / low 間の response 差は modest → DLL3 expression cutoff は現在不要 (companion diagnostic なし) だが、DLL3-negative tumor は resistant

臨床位置づけ

SCLC Treatment Landscape 2026

Treatment Line	標準治療	Tarlatamab の位置
1L	Platinum/etoposide + IO (IMpower133 / CASPIAN)	DeLLphi-305 で concurrent/maintenance 検証中
1L maintenance	PD-L1 inhibitor 継続 / lurbinectedin+atezo (IMforte)	DeLLphi-303: mOS 25.3 mo (phase Ib)
2L (all comers)	Tarlatamab (DeLLphi-304)	New standard of care — OS HR 0.60
3L+	Lurbinectedin / topotecan / platinum re-challenge	Post-tarlatamab options

2L Standard of Care (DeLLphi-304 ベース)

• Mountzios et al. NEnglJMed 2025 に基づき、platinum-based chemo (± IO) 後に進行した ES-SCLC の 2L new standard。Prior IO 患者でも ORR 51% → IO 後の BiTE は有効
• Platinum-sensitive vs resistant: DeLLphi-304 subgroup で CTFI ≥90 日 / <90 日 いずれも chemotherapy に対する OS benefit 確認 → platinum sensitivity に非依存
• Lurbinectedin との positioning: 同じ 2L setting で Lurbinectedin (ORR 35%) と競合していたが、DeLLphi-304 で tarlatamab が chemotherapy arm (lurbinectedin 含む) に OS superiority 実証 → tarlatamab preferred。Lurbinectedin は CRS ハイリスク / 高齢 / DLL3-low での代替

1L Maintenance への展開

• DeLLphi-303 の mOS 25.3 mo (Paulson et al. LancetOncol 2025) は historical control (12-13 mo) の 約 2 倍 → DeLLphi-305 confirmation で 1L paradigm shift の可能性
• IMforte (lurbinectedin + atezo maintenance: mOS 13.2 mo from randomization) との関係: DeLLphi-303 (mOS 25.3 mo) は cross-trial comparison だが numerically superior。将来的に tarlatamab maintenance vs lurbinectedin + atezo maintenance の head-to-head が必要

LCNEC / Histological Transformation

• SCLC-like LCNEC: Nassar et al. NatCommun 2025 / George et al. NatCommun 2018 で定義された SCLC-like LCNEC (RB1/TP53 loss + NE markers + DLL3 高発現) は tarlatamab off-label / basket trial の候補
• NSCLC → SCLC transformation: EGFR-mutant NSCLC の osimertinib 耐性後 SCLC transformation (約5-15%) では DLL3 が de novo 発現 → tarlatamab が治療 option (Sabari et al. NatRevClinOncol 2017)

毒性管理の実践

• CRS: Step-up dosing + dexamethasone premedication で grade 3+ 約3% に制御。大半は C1 (特に C1D1) に集中し、C2 以降は CRS 頻度が大幅低下 → 外来投与移行可能
• ICANS: Grade 1-2 約5%。Neurological baseline assessment + routine monitoring
• 全体: Grade 3+ AE は 約30%。myelosuppression がない点が chemotherapy に対する safety advantage。治療持続性が高く、長期投与で cumulative toxicity は minimal

Open Questions

• DeLLphi-305 1L confirmation: Tarlatamab + chemo-IO concurrent/maintenance が standard 1L (platinum/etoposide + IO) に OS benefit を追加するか。CRS + myelosuppression の overlapping toxicity management が key。DeLLphi-303 の mOS 25.3 mo signal の phase III reproduction
• DLL3 loss と acquired resistance monitoring: MYC-driven NE→non-NE transition による DLL3 loss の non-invasive detection。cfDNA methylation (Chemi et al. NatCancer 2022) / cfDNA ASCL1 methylation pattern による dynamic subtype monitoring
• IO combination での T cell exhaustion 克服: DeLLphi-303/305 の tarlatamab + anti-PD-L1 combination で T cell exhaustion marker (PD-1 / TIM-3 / LAG-3) の kinetics。ICI が BiTE-redirected T cell の exhaustion を rescue するか
• 最適 2L 後 sequencing: Tarlatamab 2L PD 後の 3L options (lurbinectedin / topotecan / platinum re-challenge / DLL3 CAR-T) の最適順序。Tarlatamab-resistant clone (DLL3-low / non-NE) への next strategy
• DLL3 CAR-T vs BiTE: Off-the-shelf BiTE advantage vs autologous CAR-T の deeper / more durable response 可能性。Solid tumor barriers (T cell trafficking / TME immunosuppression / exhaustion) の CAR-T での克服 approach (armored CAR-T: Zuo et al. CancerCell 2026)
• CRS 予防最適化: Step-up 以外の prophylactic strategy (prophylactic tocilizumab / ruxolitinib / dasatinib pre-medication)。CRS risk prediction biomarker の探索
• IMforte (lurbinectedin+atezo maintenance) vs DeLLphi-305 (tarlatamab maintenance) : 1L maintenance の optimal regimen。Head-to-head comparison の necessity。Sequential approach (IMforte maintenance → tarlatamab 2L) の feasibility
• LCNEC / extrapulmonary NEC expansion: SCLC-like LCNEC / GI-NEC / cervical SCNEC での DLL3 発現頻度と tarlatamab activity の prospective validation
• Histological transformation context: NSCLC→SCLC transformation 後の DLL3 発現 durability と tarlatamab response

重要論文 Top 10

1. ★★★★★ Mountzios et al. NEnglJMed 2025 — DeLLphi-304 Phase III — SCLC 2L 初の OS superiority 実証
2. ★★★★★ Paulson et al. LancetOncol 2025 — DeLLphi-303 — 1L maintenance mOS 25.3 mo
3. ★★★★★ Saunders et al. SciTranslMed 2015 — DLL3 as therapeutic target の発見 — paradigm 原点
4. ★★★★ Giffin et al. ClinCancerRes 2021 — AMG 757 preclinical — BiTE platform validation
5. ★★★★★ Rudin et al. NatRevCancer 2019 — SCLC 4-subtype taxonomy — DLL3 発現の subtype 依存性

関連エンティティ

• Drug class: DLL3-targeted-therapy (parent class page — Rova-T 比較、DLL3 biology 詳細), BiTE-bispecific (platform 共通)
• 標的: DLL3 (gene page), CD3ε
• 競合 (2L SCLC) : Lurbinectedin (IMforte で 1L maintenance に re-position), Irinotecan-Topotecan (3L option)
• 併用相手: Durvalumab / Atezolizumab (DeLLphi-303/305), Platinum-chemotherapy + Etoposide (DeLLphi-305 concurrent)
• Concept: SCLC-molecular-subtypes (DLL3 発現の subtype 依存性), Lineage-plasticity (NE→non-NE 転換による DLL3 loss / resistance), NE-non-NE-transition
• 試験: DeLLphi-300 / DeLLphi-301 / DeLLphi-303 / DeLLphi-304 / DeLLphi-305
• ドメイン: lung-cancer-treatment, novel-cancer-modalities

関連論文

直近 30 件のみ表示中 (関連 39 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Mavrikios et al. AnnOncol 2026 — Lung cancer brain metastases management at the dawn of personalized medicine are we ready to break the barriers
• Lu et al. JClinOncol 2026 — Multicenter cohort study of original or substitute systemic therapy with or without brain radiotherapy for

Basic-Oncogene and genetics

• Ireland et al. CancerCell 2020 — MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate

Basic-Others

• Winslow et al. CancerDiscov 2026 — A roadmap to transform lung cancer outcomes priorities in biology, therapeutic innovation, early detection, prevention
• Lim et al. Cell 2017 — The principles of engineering immune cells to treat cancer

Clinical-Methodology

• Lemaire et al. ClinPharmTher 2023 — From cold to hot changing perceptions and future opportunities for quantitative systems pharmacology modeling in cancer

Clinical-NEC

• Sen et al. LancetOncol 2025 — Pulmonary neuroendocrine neoplasms the molecular landscape, therapeutic challenges, and diagnosis and management
• George et al. NatCommun 2018 — Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade
• Nassar et al. NatCommun 2025 — Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

Clinical-NSCLC-Driver negative

• Li et al. FrontImmunol 2026 — The application and challenges of immune checkpoint inhibitors in lung cancer therapy

Clinical-NSCLC-EGFR

• Okamoto et al. LungCancer 2026 — Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and

Clinical-Novel modalities

• Hofman et al. LungCancer 2026 — New biomarkers for antibody-drug conjugates in lung cancer the pathologist’s perspective
• Yasunaga et al. MethodMolBiol 2026 — Bispecifc antibodies methods and protocols

Clinical-SCLC

• Rekhtman et al. CancerDiscov 2025 — Chromothripsis-mediated small cell lung carcinoma
• Morgensztern et al. ClinCancerRes 2019 — Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing,
• Giffin et al. ClinCancerRes 2021 — AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in
• Guan et al. CritRevOncolHematol 2026 — Overcoming immunotherapy resistance in extensive-stage small cell lung cancer insights into mechanisms and therapeutic
• Dai et al. CurrTreatOptionsOncol 2026 — Addressing unmet needs in the management of small cell lung cancer treatment of brain metastases, quality of life, and
• Liu et al. FrontPharmacol 2026 — Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based
• Li et al. JCOGlobOncol 2025 — Durvalumab in limited-stage small cell lung cancer clinical triumph and toward sustainable value
• Ott et al. JClinOncol 2017 — Pembrolizumab in patients with extensive-stage small-cell lung cancer results from the phase ib KEYNOTE-028 study
• Khurshid et al. JClinOncol 2023 — Systemic therapy for small-cell lung cancer ASCO-ontario health (cancer care ontario) guideline
• Tian et al. JHematolOncol 2019 — Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small
• Baize et al. LancetOncol 2020 — Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed SCLC
• Paulson et al. LancetOncol 2025 — Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after
• Reguart et al. LancetRespirMed 2025 — Rethinking immunotherapy in patients with SCLC with poor performance status
• Horn et al. NEnglJMed 2018 — First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
• Mountzios et al. NEnglJMed 2025 — Tarlatamab in small-cell lung cancer after platinum-based chemotherapy
• Iams et al. NatRevClinOncol 2020 — Immunotherapeutic approaches for small-cell lung cancer
• Rudin et al. NatRevDisPrimers 2021 — Small-cell lung cancer